Endogenics · Mechanistic disease simulation

The mechanistic intelligence layer for disease biology.

Turn fragmented disease data into causal answers for high-stakes program decisions.

Core solutions

The four program decisions

The critical question

Does this mechanism of action belong in this indication?

Mechanistic disease graphs and their simulations show whether the disease biology can be moved by this mechanism of action, and where the chain breaks.

The shift · The causal divide

Correlation finds patterns. Causality discovers medicines.

Generative AI has automated molecular design, but biology remains the ultimate bottleneck. Today, more capital than ever is chasing fewer novel targets,1,2 because traditional tools match patterns without understanding mechanisms.

Statistical machine learning excels where data is abundant, but foundational disease biology is inherently sparse and dynamic. Black-box correlations fail in the clinic because they cannot explain why a disease progresses or how a pathway compensates.

BioFi bridges this divide with dynamic biological intelligence—simulating how complex human systems evolve in continuous time to turn uncertain hypotheses into mechanisms you can test.

  1. 1L.E.K. Consulting (2025), Innovative mechanisms
  2. 2McKinsey & Company (2026), AI drug discovery: focusing on what matters most

The platform & technology

Endogenics™

Endogenics pairs agentic workflows with specialized dynamic simulation. Proprietary pipelines translate patient multi-omics datasets into structured, interconnected disease systems—modeling how human biology behaves, evolves, and responds to intervention in continuous time.

The compounding platform advantage

  • Asset-Light Agility

    Operates directly on existing patient and multi-omics data, augmenting and compounding the evidence you already have.

  • Continuous Asset Intelligence

    Partners own their calibrated disease models that improve with every simulation cycle and additional evidence that is fed into the platform and generated from it.

Our team

Diverse in experience, aligned in vision

  • Thomas Nirnberger

    Background

    Background in Biotechnology and Medical Informatics; +10 years experience in the Life Science sector including AstraZeneca, managing cross-functional projects across the drug R&D value chain.

    Thomas Nirnberger

    Co-founder & Chief Executive Officer

  • Bill Crowley

    Background

    Engineer and MBA, former treasurer and inventor at Hewlett-Packard and CEO at Crowley-Davis Research. Inventor of cutting-edge technologies, including algorithms powering the HP-80 and HP-12c pocket calculators

    Bill Crowley

    Co-founder & Chairman

  • Clement Surville

    Background

    Engineer and theoretical physicist with a distinguished academic career at the Max Planck Institute for Astronomy and University of Zürich. Expert in high performance computing and software engineering. Previously simulated the formation of planets, an invaluable experience he now applies to biology.

    Clement Surville

    Director Computational Science

  • Kristina Djordjevic

    Background

    Industrial research and development technician turned data scientist and bioinformatician. Broad understanding of the biopharmaceutical industry with specialist skills in computational biology.

    Kristina Djordjevic

    Director Bioinformatics

  • Léonard Gable

    Background

    Bioengineer from the EPFL turned full stack software developer. Extensive experience in web application and infrastructure development.

    Léonard Gable

    Director Software Engineering

  • Bernard Deffarges

    Background

    CEO of LLAAMA. +20 years of software engineering experience in the pharmaceutical industry (Roche, Actelion, Idorsia). Experience in building high performing software development teams. Distributed systems enthusiast.

    Bernard Deffarges

    Technical Advisor

Bring a program decision. Leave with a causal answer.

Bring us a live program question

Our mission

No drug program should fail for a biological truth we could have known before the trial.

Behind every clinical trial is a patient waiting for a life-changing answer. Developing novel medicines is one of humanity's toughest scientific challenges, where unexpected biological complexities can derail even the most dedicated R&D efforts. BioFi exists to give drug development teams clarity where it matters most. By uncovering the true causal drivers of disease before trials begin, we help biopharma match the right target to the right patient population from the start, ensuring every program advances with conviction and reaches the people who need it.